Arnd Nusch

TL;DR: Among patients receiving initial systemic treatment for HR-positive, HER2-negative advanced breast cancer, the duration of progression-free survival was significantly longer among those receiving ribociclib plus letrozole than among those received placebo plus let rozole, with a higher rate of myelosuppression in the ribocIClib group.

TL;DR: Ribociclib plus fulvestrant might represent a new first- or second-line treatment option in hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer.

TL;DR: In this paper, ribociclib plus fulvestrant showed a greater benefit with regard to progression-free survival than fulvestrants alone in postmenopaugmentation.

TL;DR: Data suggest selective internal radiotherapy (SIRT) in third-line or subsequent therapy for metastatic colorectal cancer has clinical benefit in patients with coloreCTal liver metastases with liver-dominant disease after chemotherapy.

TL;DR: In conclusion, lapatinib-capecitabine efficacy may have been affected by previous exposure to a trastuzumab regimen and/or when treatment was given as first- or second-line therapy in the metastatic setting, and no difference was detected between lapatinb-cape citabine and trastzumab-cape Citabine for the incidence of CNS metastases.